Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798427 | 0.86 | ALOX15 (0.50) | ALOX15NFE2L2CTSK | |
| SCHEMBL25990286 | 0.81 | ALOX15 (0.55) | ALOX15NFE2L2MEN1KMT2A | |
| SCHEMBL5605059 | 0.78 | ALOX15 (0.61) | ALOX15NFE2L2 | |
| SCHEMBL5605056 | 0.78 | ALOX15 (0.61) | ALOX15NFE2L2 | |
| SCHEMBL585939 | 0.78 | ALOX15 (0.61) | ALOX15NFE2L2 | |
| SCHEMBL30372415 | 0.76 | ALOX15 (0.52) | ALOX15NFE2L2 | |
| SCHEMBL25990057 | 0.76 | ALOX15 (0.58) | ALOX15NFE2L2 | |
| SCHEMBL874243 | 0.76 | ALOX15 (0.58) | ALOX15NFE2L2 | |
| SCHEMBL6560967 | 0.76 | ALOX15 (0.58) | ALOX15NFE2L2 | |
| SCHEMBL19506885 | 0.75 | ALOX15 (0.57) | ALOX15NFE2L2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | PURDUE RESEARCH FOUNDATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | PURDUE RESEARCH FOUNDATION (US) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | HBB, BCAT1, BCAT2 | ALOX15 3850/4885NFE2L2 3435/4885POLB 976/4885 |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | HBB, BCAT1, BCAT2 | ALOX15 4007/4885NFE2L2 3185/4885POLB 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.